Lauren Bonati
MOHS-Micrographic Surgery · Edwards, CONPI 1982947891
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,350 of the $1,606 with a category attached, or 84.0%. AbbVie accounts for 86.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,371 and has fallen 99.0% since, to $14 in 2025. That places this record below the midpoint for mohs-micrographic surgery clinicians in CO, where the typical reported total is $1,865.
Across 14 payments — averaging $114.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$66
- Galderma Laboratories, L.p.$55
- Sanofi$31
- Incyte Corporation$29
- Organogenesis Inc.$23
- plus $16 from 1 others
Across 5 payments — averaging $3969.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$20K
What the payments were for
- Consulting fees$1,35084%
- Food & beverage$25616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 4 | $1,385 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Galderma Laboratories, L.p. | 3 | $55 |
| Sanofi | 1 | $31 |
| Incyte Corporation | 1 | $29 |
| Organogenesis Inc. | 1 | $23 |
| Aclaris Therapeutics, Inc. | 1 | $16 |
How this compares
$1,606 in reported general payments places this provider in the 40th percentile of 37 mohs-micrographic surgery providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluocinonide | 41 | $1,729 |
| Clobetasol Propionate | 25 | $1,202 |
| Minoxidil | 42 | $683 |
| ValacyclovirValacyclovir Hcl | 36 | $563 |
| Ketoconazole | 28 | $502 |
| Triamcinolone Acetonide | 58 | $430 |
| Spironolactone | 18 | $428 |
| Cephalexin | 55 | $375 |
| Doxycycline Hyclate | 29 | $365 |
| Mupirocin | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Edwards
- Karen NernEdwards$28K
- Joel CohenGreenwood Village$426K
- Shawn AllenBoulder$69K
- Kevin MottLoveland$33K
- Vinh ChungColorado Springs$10K
- Brett MathesonColorado Spgs$10K
- Misha MillerDenver$5K
- Joseph WildeFort Collins$5K
- Samantha GhiselliGlendale$5K
- Zachary BurrGrand Junction$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.